Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Topotecan, and Estramustine in Metastatic Hormone-Refractory Prostate Cancer
NCT00084565Phase 2Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Start
- Nov 2003
- Primary completion
- Nov 2004
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of paclitaxel, topotecan, estramustine in prostate cancer (PCa), sponsored by Fox Chase Cancer Center. Planned start Nov 2003; status: withdrawn.
02
Drugs
paclitaxeltopotecanestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00084565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084565.